Narcolepsy - Clinical Characteristics, Aetiopathophysiology, Diagnosis and Treatment- A Global Review
Pharmaceutical Science-Pharmaceutical Sciences
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P180-197Keywords:
Narcolepsy, Cataplexy, Orexin, SOREMs, EDSAbstract
Narcolepsy is a rare chronic, debilitating sleep disease that is currently categorized as different types of CNS hypersomnia in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Narcolepsy type 1 (NT1) is narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons that produce hypocretin, while NT2 is narcolepsy without cataplexy and normal hypocretin levels. Hypocretin is a neurotransmitter that regulates sleep, body homeostasis, emotions, and behavior and has extensive projections to a variety of brain locations, including the locus coeruleus (norepinephrine neurons), tuberomammillary nucleus, raphe nucleus (serotonergic neurons), and dopaminergic neurons (ventral tegmental areas). Hypocretin is a neurotransmitter that not only excites the central nervous system, but also affects serotonin and histamine levels. Hypocretin is a neurotransmitter that regulates the activity of serotonin, histamine, dopamine, acetylcholine, GABA, and glutamate in the central nervous system. It is now understood to be a separate condition with its own pathogenesis and neurochemical abnormalities. Narcolepsy affects men and women equally and has a prevalence of 20–60 cases per 100,000. The highest rate is found in Japan, while the lowest is found in Israel. There is no cure for narcolepsy, despite a reliable pathophysiological hypothesis linking NT1 to an autoimmune process that damages hypocretin-producing cells. Because current symptomatic pharmaceutical treatments are not 100% effective for all symptoms, behavioral therapies play a synergistic role in the disease treatment. We examine the narcolepsy diagnostic and treatment options, including symptomatic pharmacological treatments as well as behavioral and psychological measures that may help doctors to improve narcoleptic patients' quality of life.
References
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest.2014;146(5):1387-94. doi: 10.1378/chest.14-0970, PMID 25367475.
Kim MK, Park HJ, Kim SR, Choi YK, Bae SK, Bae MK. Involvement of heme oxygenase-1 in orexin-A-induced angiogenesis in vascular endothelial cells. Korean J Physiol Pharmacol. 2015;19(4):327-34. doi: 10.4196/kjpp.2015.19.4.327, PMID 26170736.
Dye TJ, Gurbani N, Simakajornboon N. Epidemiology and pathophysiology of childhood narcolepsy. Paediatr Respir Rev. 2018;25:14-8. doi: 10.1016/j.prrv.2016.12.005, PMID 28108192.
Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, Ueta Y. Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neurosci Res. 2008;61(1):99-105. doi: 10.1016/j.neures.2008.01.017, PMID 18355936.
Franceschini C, Pizza F, Antelmi E, Folli MC, Plazzi G. Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. Sleep Breath. 2020;24(2):615-27. doi: 10.1007/s11325-019-01894-4, PMID 31290083.
Honda Y. Clinical features of narcolepsy: Japanese experiences.
Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep. 1987;10(6):608-9. PMID 3432862.
Challamel MJ, Mazzola ME, Nevsimalova S, Cannard C, Louis J, Revol M. Narcolepsy in children. Sleep. 1994;17(8);Suppl:S17-20. doi: 10.1093/sleep/17.suppl_8.s17, PMID 7701194.
al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H et al. A community survey of neurological disorders in Saudi Arabia: the thugbah study. Neuroepidemiology. 1993;12(3):164-78. doi: 10.1159/000110316, PMID 8272177.
Jennum P, Thorstensen EW, Pickering L, Ibsen R, Kjellberg J. Morbidity and mortality of middle-aged and elderly narcoleptics. Sleep Med. 2017;36:23-8. doi: 10.1016/j.sleep.2017.03.029, PMID 28735916.
Rocca FL, Pizza F, Ricci E, Plazzi G. Narcolepsy during childhood: an update. Neuropediatrics vol. Neuropediatrics. 2015;46(3):181-98. doi: 10.1055/s-0035-1550152, PMID 25961600.
Wise MS, Lynch J. Narcolepsy in children. Semin Pediatr Neurol. 2001;8(4):198-206. doi: 10.1053/spen.2001.29475, PMID 11768782.
Pizza F et al. Primary progressive narcolepsy type 1: the other side of the coin. Neurology vol. Neurology. 2014;83(23):2189-90. doi: 10.1212/WNL.0000000000001051, PMID 25355832.
Luca G, Haba-Rubio J, Dauvilliers Y, Lammers GJ, Overeem S, Donjacour CE et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: A European Narcolepsy Network study. J Sleep Res. 2013;22(5):482-95. doi: 10.1111/jsr.12044, PMID 23496005.
Lopez R, Doukkali A, Barateau L, Evangelista E, Chenini S, Jaussent I et al. Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence. Sleep. 2017;40(12). doi: 10.1093/sleep/zsx164, PMID 29099966.
Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Clinical/Scientific Notes NORMALIZATION OF HYPOCRETIN-1 IN NARCOLEPSY AFTER Intravenous IMMUNOGLOBULIN TREATMENT. Available from: http://www.neurology.org [cited 10/10/2022].
Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U et al. Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519-39. doi: 10.1038/s41582-019-0226-9, PMID 31324898.
Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100. doi: 10.1038/nrdp.2016.100, PMID 28179647.
Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens. 1984;24(5):316-9. doi: 10.1111/j.1399-0039.1984.tb02144.x, PMID 6597978.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. THE Lancet ·. Vol. 355; 2000.
Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Available from: http://www.cbs.dtu.dk/services/SignalP/ [cited 10/10/2022].
Krahn LE. Reevaluating spells initially identified as cataplexy. Sleep Med. 2005;6(6):537-42. doi: 10.1016/j.sleep.2005.04.006, PMID 15994123.
Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: A laboratory perspective. Sleep. 1986;9(1):205-15. doi: 10.1093/sleep/9.1.205.
Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9(4):269-310. doi: 10.1016/j.smrv.2005.03.004, PMID 16006155.
Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562(7725):63-8. doi: 10.1038/s41586-018-0540-1, PMID 30232458.
Lippert J, Young P, Gross C, Meuth SG, Dräger B, Schirmacher A et al. Specific T-cell activation in peripheral blood and cerebrospinal fluid in central disorders of hypersomnolence. Sleep. 2019;42(2). doi: 10.1093/sleep/zsy223, PMID 30445542.
Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50(2);Suppl 1:S16-22. doi: 10.1212/wnl.50.2_suppl_1.s16, PMID 9484418.
Tafti M, Hor H, Dauvilliers Y, Lammers GJ, Overeem S, Mayer G et al. DQB1 Locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2014;37(1):19-25. doi: 10.5665/sleep.3300.
Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X et al. HLA-DPB1 and HLA class i confer risk of and protection from narcolepsy. Am J Hum Genet. 2015;96(1):136-46. doi: 10.1016/j.ajhg.2014.12.010, PMID 25574827.
Degn M, Dauvilliers Y, Dreisig K, Lopez R, Pfister C, Pradervand S et al. Rare missense mutations in P2RY11 in narcolepsy with cataplexy. Brain. 2017;140(6):1657-68. doi: 10.1093/brain/awx093, PMID 28460015.
Khatami R et al. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. THE Lancet ·. Available from: http://www.thelancet.com. Vol. 363; 2004.
Dahmen N, Tonn P. Season of birth effect in narcolepsy. Neurology. 2003;61(7):1016-7. doi: 10.1212/01.wnl.0000080371.15688.30, PMID 14557589.
Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136(8):2486-96. doi: 10.1093/brain/awt187, PMID 23884811.
Saariaho AH, Vuorela A, Freitag TL, Pizza F, Plazzi G, Partinen M et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun. 2015;63:68-75. doi: 10.1016/j.jaut.2015.07.006, PMID 26227560.
Luo G, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci U S A. 2018;115(52):E12323-32. doi: 10.1073/pnas.1818150116, PMID 30541895.
Hidalgo H, Kallweit U, Mathis J, Bassetti CL. Post tick-borne encephalitis virus vaccination narcolepsy with cataplexy. Sleep. 2016;39(10):1811-4. doi: 10.5665/sleep.6160, PMID 27397572.
Koepsell TD, Longstreth WT, Ton TGN. Medical exposures in youth and the frequency of narcolepsy with cataplexy: A population-based case-control study in genetically predisposed people. J Sleep Res. 2010;19(1 Pt 1):80-6. doi: 10.1111/j.1365-2869.2009.00756.x, PMID 19732319.
Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120(3):713-9. doi: 10.1172/JCI41366, PMID 20160349.
Kallweit U, Bassetti CLA, Oberholzer M, Fronczek R, Béguin M, Strub M et al. Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis: Six new cases and a literature review. J Neurol. 2018;265(9):2071-8. doi: 10.1007/s00415-018-8949-x, PMID 29974206.
Knudsen S et al. No normalization of hypocretin-1 deficiency or narcoleptic phenotype after early ivig treatment in post-H1N1 vaccination narcolepsy with cataplexy. Eur J Neurol. 2011;2.
Black JL, Silber MH, Krahn LE, Fredrickson PA, Pankratz VS, Avula R et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep. 2005;28(4):427-31. doi: 10.1093/sleep/28.4.427, PMID 16171287.
Hartmann FJ, Bernard-Valnet R, Quériault C, Mrdjen D, Weber LM, Galli E et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J Exp Med. 2016;213(12):2621-33. doi: 10.1084/jem.20160897, PMID 27821550.
Morandin M, Bruck D. Send Orders of Reprints at bspsaif@emirates.net.ae The Open Sleep Journal. Vol. 6; 2013.
Khatami R, Luca G, Baumann CR, Bassetti CL, Bruni O, Canellas F et al. The European Narcolepsy Network (EU-NN) database. J Sleep Res. 2016;25(3):356-64. doi: 10.1111/jsr.12374, PMID 26809504.
Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res. 2004;13(4):395-406. doi: 10.1111/j.1365-2869.2004.00422.x, PMID 15560774.
Guilleminault C, Phillips R, Dement WC. A syndrome OF hypersomnia with automatic BEHAVIOR 1. Electroencephalogr Clin Neurophysiol. 1975;38(4):403-13. doi: 10.1016/0013-4694(75)90264-3, PMID 46820.
Fatigue Severity Scale (FSS, English version)*.
Antelmi E, Vandi S, Pizza F, Liguori R, Plazzi G. Parkinsonian tremor persisting during cataplexy. Sleep Med. 2016;17:174-6. doi: 10.1016/j.sleep.2015.07.021, PMID 26459690.
Chabas D, Taheri S, Renier C, Mignot E. The genetics of narcolepsy. Annu Rev Genomics Hum Genet. 2003;4:459-83. doi: 10.1146/annurev.genom.4.070802.110432, PMID 14527309.
Wilson SAK. The narcolepsies. Brain. 1928;51(1):63-109. doi: 10.1093/brain/51.1.63.
Pizza F, Antelmi E, Vandi S, Meletti S, Erro R, Baumann CR et al. The distinguishing motor features of cataplexy: a study from video-recorded attacks. Sleep. 2018;41(5). doi: 10.1093/sleep/zsy026, PMID 29425380.
Attarian HP, Schenck CH, Mahowald MW. Presumed REM sleep behavior disorder arising from cataplexy and wakeful dreaming. Sleep Med. 2000;1(2):131-3. doi: 10.1016/s1389-9457(99)00013-1, PMID 10767654.
Poryazova R, Khatami R, Werth E, Bassetti CL. Weak with sex: sexual intercourse as a trigger for cataplexy. J Sex Med. 2009;6(8):2271-7. doi: 10.1111/j.1743-6109.2009.01328.x, PMID 19493288.
Pa RKES, Dunn G. The clinical diagnosis of the narcoleptic syndrome. J Sleep Res. 1998;7.
Baraitser M, Parkes JD. Genetic study of narcoleptic syndrome. J Med Genet. 1978;15(4):254-9. doi: 10.1136/jmg.15.4.254, PMID 712757.
YOSS RE, DALY DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin. 1957;32(12):320-8. PMID 13441766.
Imlah NW. Narcolepsy in identical twins. J Neurol Neurosurg Psychiatry. 1961;24:158-60. doi: 10.1136/jnnp.24.2.158, PMID 13717600.
Wamsley E, Donjacour CEHM, Scammell TE, Lammers GJ, Stickgold R. Delusional confusion of dreaming and reality in narcolepsy. Sleep. 2014;37(2):419-22. doi: 10.5665/sleep.3428, PMID 24501437.
Oosterloo M, Lammers GJ, Overeem S, de Noord I, Kooij JJS. Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder. Psychiatry Res. 2006;143(2-3):293-7. doi: 10.1016/j.psychres.2006.02.009, PMID 16854470.
Bayard S, Croisier Langenier M, Cochen De Cock V, Scholz S, Dauvilliers Y. Executive control of attention in narcolepsy. PLOS ONE. 2012;7(4):e33525. doi: 10.1371/journal.pone.0033525, PMID 22558075.
Hublin C et al. The Prevalence of Narcoleosv: an Epidemiological Study ofthe Finnish Twin Cohort; 1994.
Roberts HJ. Obesity due to the syndrome OF narcolepsy and diabetogenic hyperinsulinism: clinical and therapeutic observations on 252 patients*. Journal of the American Geriatrics Society. 1967;15(8):721-43. doi: 10.1111/j.1532-5415.1967.tb02307.x.
Poli F, Pizza F, Mignot E, Ferri R, Pagotto U, Taheri S et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep. 2013;36(2):175-81. doi: 10.5665/sleep.2366, PMID 23372264.
Pdf of narcolepsy symptoms name.
Naumann A, Daum I. Narcolepsy: Pathophysiology and neuropsychological changes. Behav Neurol. 2003;14(3-4):89-98. doi: 10.1155/2003/323060, PMID 14757984.
Broughton R, Dunham W, Weisskopf M, Rivers M. Night sleep does not predict day sleep in narcolepsy. Electroencephalogr Clin Neurophysiol. 1994;91(1):67-70. doi: 10.1016/0013-4694(94)90019-1.
Trotti LM. Waking up is the hardest thing I do all day: Sleep inertia and sleep drunkenness. Sleep Med Rev. 2017;35:76-84. doi: 10.1016/j.smrv.2016.08.005, PMID 27692973.
Harsh J, Peszka J, Hartwig G, Mitler M. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res. 2000;9(3):309-16. doi: 10.1046/j.1365-2869.2000.00217.x, PMID 11012872.
Pizza F, Tartarotti S, Poryazova R, Baumann CR, Bassetti CL. Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: A systematic analysis of 35 consecutive patients. Eur Neurol. 2013;70(1-2):22-6. doi: 10.1159/000348719, PMID 23689193.
Plazzi G, Ferri R, Antelmi E, Bayard S, Franceschini C, Cosentino FI et al. Restless legs syndrome is frequent in narcolepsy with cataplexy patients. Sleep. 2010;33(5):689-94. doi: 10.1093/sleep/33.5.689, PMID 20469811.
Dodet P, Chavez M, Leu-Semenescu S, Golmard JL, Arnulf I. Lucid dreaming in narcolepsy. Sleep. 2015;38(3):487-97. doi: 10.5665/sleep.4516, PMID 25348131.
Plazzi G, Moghadam KK, Maggi LS, Donadio V, Vetrugno R, Liguori R et al. Autonomic disturbances in narcolepsy. Sleep Med Rev. 2011;15(3):187-96. doi: 10.1016/j.smrv.2010.05.002, PMID 20634114.
Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14-8. doi: 10.1016/j.sleep.2017.11.1125, PMID 29482805.
Bladin PF. Narcolepsy - Cataplexy and psychoanalytic theory of sleep and dreams. J Hist Neurosci. 2000;9(2):203-17. doi: 10.1076/0964-704x(200008)9:2;1-y;ft203, PMID 11608942.
Orellana C, Villemin E, Tafti M, Carlander B, Besset A, Billiard M. Life events in the year preceding the onset of narcolepsy. Sleep. 1994;17(8);Suppl:S50-3. doi: 10.1093/sleep/17.suppl_8.s50, PMID 7701200.
Fortuyn HA, Mulders PC, Renier WO, Buitelaar JK, Overeem S. Narcolepsy and psychiatry: an evolving association of increasing interest. Sleep Med. 2011;12(7):714-9. doi: 10.1016/j.sleep.2011.01.013, PMID 21689985.
Plazzi G, Khatami R, Serra L, Pizza F, Bassetti CL. Pseudocataplexy in narcolepsy with cataplexy. Sleep Med. 2010;11(6):591-4. doi: 10.1016/j.sleep.2010.03.004, PMID 20471315.
Ohayon MM, Black J, Lai C, Eller M, Guinta D, Bhattacharyya A. Increased mortality in narcolepsy. Sleep. 2014;37(3):439-44. doi: 10.5665/sleep.3470, PMID 24587565.
Zisapel N. Sleep and sleep disturbances: Biological basis and clinical implications. Cell Mol Life Sci. 2007;64(10):1174-86. doi: 10.1007/s00018-007-6529-9, PMID 17364142.
Zeman A et al. Clinical Review Narcolepsy and Excessive Daytime Sleepiness. Available from: http://www.sleeping.org.uk [cited 10/10/2022].
Bauer I. Die Privatsphäre der Patienten.
Aldrich MS, Rogers AE, Aldrich S. Exacerbation of human cataplexy by prazosin. Sleep vol. Available from: https://academic.oup.com/sleep/article-abstract/12/3/254/2742674. Vol. 12; 2018.
Aldrich M, Hollingsworth Z, Penney J. Autoradiographic studies of post-mortem human narcoleptic brain*. Neurophysiologie Clinique/Clinical Neurophysiology. 1993;23(1):35-45. doi: 10.1016/S0987-7053(05)80281-3.
Boehme RE, Baker TL, Mefford IN, Barchas JD, Dement WC, Ciaranello RD. Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 1984;34(19):1825-8. doi: 10.1016/0024-3205(84)90675-1, PMID 6539848.
F, K.F., Guilleminault C, Berger PA, Barchas JD. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia materials and methods patient population.
Beckstead RM, Wooten GF, Trugman JM. Distribution of D1 and D2 dopamine receptors in the basal ganglia of the cat determined by quantitative autoradiography. J Comp Neurol. 1988;268(1):131-45. doi: 10.1002/cne.902680113.
Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and grade assessment. J Clin Sleep Med. 2021;17(9):1895-945. doi: 10.5664/jcsm.9326, PMID 34743790.
Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(22):5731-6. doi: 10.1073/pnas.1700499114, PMID 28507129.
Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499-511. doi: 10.1016/S0140-6736(07)60237-2, PMID 17292770.
Mefford IN, Baker TL, Boehme R, Foutz AS, Ciaranello RD, Barchas JD et al. Narcolepsy: Biogenic amine deficits in an animal model. Science. 1983;220(4597):629-32. doi: 10.1126/science.6188216, PMID 6188216.
Lin L et al. The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the hypocretin (orexin) receptor 2 Gene rhythmicity in Drosophila and/or mammals (Huang et al. protein-protein interactions within the PAS domain and transcription-translation feedback loops have been established to be primary * Center for Narcolepsy factors in the generation of circadian rhythmicity at the Department of Psychiatry cellular level (Huang et al. Cell vol. Vol. 98; 1999.
España RA, McCormack SL, Mochizuki T, Scammell TE. Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep. 2007;30(11):1417-25. doi: 10.1093/sleep/30.11.1417, PMID 18041476.
Burgess CR, Scammell TE. Narcolepsy: Neural mechanisms of sleepiness and cataplexy. J Neurosci. 2012;32(36):12305-11. doi: 10.1523/JNEUROSCI.2630-12.2012, PMID 22956821.
Lee RU, Radin JM. A population-based epidemiologic study of adult-onset narcolepsy incidence and associated risk factors, 2004-2013. J Neurol Sci. 2016;370:29-34. doi: 10.1016/j.jns.2016.08.026, PMID 27772778.
Vandi S, Pizza F, Antelmi E, Neccia G, Iloti M, Mazzoni A et al. A standardized test to document cataplexy. Sleep Med. 2019;53:197-204. doi: 10.1016/j.sleep.2017.08.021, PMID 29276000.
Baumann CR, Khatami R, Werth E, Bassetti CL. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. J Neurol Neurosurg Psychiatry. 2006;77(3):402-4. doi: 10.1136/jnnp.2005.067207, PMID 16484654.
Figure 4. Available from: https://academic.oup.com/sleep/article-abstract/32/8/993/2679679 [cited 10/10/2022].
Gerashchenko D, Kohls MD, Greco M, Waleh NS, Salin-Pascual R, Kilduff TS et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci. 2001;21(18):7273-83. doi: 10.1523/JNEUROSCI.21-18-07273.2001, PMID 11549737.
Review Hypocretin System. Available from: http://neurology.thelancet.com [cited 10/10/2022].
Sakai N, Matsumura M, Lin L, Mignot E, Nishino S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci Rep. 2019;9(1):477. doi: 10.1038/s41598-018-36942-8, PMID 30679597.
Mignot E, Lin L, Finn L, Lopes C, Pluff K, Sundstrom ML et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain. 2006;129(6):1609-23. doi: 10.1093/brain/awl079, PMID 16597649.
Bassetti C, Aldrich MS. Idiopathic hypersomnia A series of 42 patients. Brain vol. Vol. 120; 1997.
Moghadam KK, Pizza F, La Morgia C, Franceschini C, Tonon C, Lodi R et al. Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. Brain. 2014;137(6):1643-55. doi: 10.1093/brain/awu069, PMID 24727570.
Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8(4):373-99. doi: 10.1016/j.sleep.2007.03.008, PMID 17470414.
Kallweit U, Schmidt M, Bassetti CL. Patient-reported measures of narcolepsy: the need for better assessment. J Clin Sleep Med. 2017;13(5):737-44. doi: 10.5664/jcsm.6596, PMID 28162143.
Phillips BA. The prevalence of multiple sleep-onset REM periods in a population-based sample. Yearbook of Pulmonary Disease. 2008;2008:293-4. doi: 10.1016/S8756-3452(08)70716-3.
Marti I, Valko PO, Khatami R, Bassetti CL, Baumann CR. Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med. 2009;10(10):1146-50. doi: 10.1016/j.sleep.2009.03.008, PMID 19464232.
Goldbart A, Peppard P, Finn L, Ruoff CM, Barnet J, Young T et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin sleep cohort. Sleep. 2014;37(6):1043-51. doi: 10.5665/sleep.3758, PMID 24882899.
Cairns A, Bogan R. Prevalence and clinical correlates of a short onset REM period (SOREMP) during routine PSG. Sleep. 2015;38(10):1575-81. doi: 10.5665/sleep.5050.
Desseilles M et al. OVER THE LAST COUPLE OF DECADES, SEVERAL STUDIES HAVE USED FUNCTIONAL neuroimaging TECHNIQUES TO INVESTIGATE THE CEREBRAL cor neuroimaging Insights into the Pathophysiology of Sleep Disorders. Vol. 31; 2008. SLEEP vol. Available from: https://academic.oup.com/sleep/article-abstract/31/6/777/2454194 [cited 10/10/2022].
Meletti S, Vaudano AE, Pizza F, Ruggieri A, Vandi S, Teggi A et al. The brain correlates of laugh and cataplexy in childhood narcolepsy. J Neurosci. 2015;35(33):11583-94. doi: 10.1523/JNEUROSCI.0840-15.2015, PMID 26290235.
Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: Characterization and impact. Sleep Med. 2014;15(5):502-7. doi: 10.1016/j.sleep.2014.01.015, PMID 24780133.
Ingravallo F, Gnucci V, Pizza F, Vignatelli L, Govi A, Dormi A et al. The burden of narcolepsy with cataplexy: How disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012;13(10):1293-300. doi: 10.1016/j.sleep.2012.08.002, PMID 23026503.
Mets MAJ, Donjacour CEHNM, Verster JC. Narcolepsy, driving and traffic safety. Sleep Sleepiness Traffic Saf. 2011. doi: 10.1007/978-3-319-23739-8_20.
Marín Agudelo HA, Jiménez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH. Cognitive behavioral treatment for narcolepsy: Can it complement pharmacotherapy? Sleep Sci. 2014;7(1):30-42. doi: 10.1016/j.slsci.2014.07.023, PMID 26483898.
Cognitive deficits in narcolepsy.
Ingravallo F, Vignatelli L, Brini M, Brugaletta C, Franceschini C, Lugaresi F et al. Medico-legal assessment of disability in narcolepsy: an interobserver reliability study. J Sleep Res. 2008;17(1):111-9. doi: 10.1111/j.1365-2869.2008.00630.x, PMID 18275561.
e Silva C, JA. Sleep disorders in psychiatry. Metabolism. 2006;55.
Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep. 2007;30(11):1445-59. doi: 10.1093/sleep/30.11.1445, PMID 18041479.
Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep vol. Available from: https://academic.oup.com/sleep/article-abstract/16/5/444/2749388. Vol. 16; 1993.
Uchiyama M, Mayer G, Meier-Ewert K. Differential effects of extended sleep in narcoleptic patients. Electroencephalogr Clin Neurophysiol. 1994;91(3):212-8. doi: 10.1016/0013-4694(94)90071-x, PMID 7522150.
Bhattarai J, Sumerall S. Current and future treatment options for narcolepsy: a review. Sleep Sci. 2017;10(1):19-27. doi: 10.5935/1984-0063.20170004, PMID 28966734.
Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs. 1984;16(6):326-34. doi: 10.1097/01376517-198412000-00009, PMID 6568258.
Agudelo HAMM-N. M-N-123 Multicomponent cognitive behavioral treatment efficacy for narcolepsy (MCBT-N). Sleep Med. 2011;12. doi: 10.1016/S1389-9457(11)70203-9.
Filardi M, Pizza F, Antelmi E, Pillastrini P, Natale V, Plazzi G. Physical activity and sleep/wake behavior, anthropometric, and metabolic profile in pediatric narcolepsy type 1. Front Neurol. 2018;9:707. doi: 10.3389/fneur.2018.00707, PMID 30197622.
Dennis CL. Peer support within a health care context: a concept analysis. Int J Nurs Stud. 2003;40(3):321-32. doi: 10.1016/s0020-7489(02)00092-5, PMID 12605954.
Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8:22. doi: 10.1186/1750-1172-8-22, PMID 23398775.
Wisor J. Modafinil as a catecholaminergic agent: Empirical evidence and unanswered questions. Front Neurol. 2013;4 OCT Preprint at:139. doi: 10.3389/fneur.2013.00139, PMID 24109471.
Schwartz JRL, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26(5):252-7. doi: 10.1097/00002826-200309000-00009, PMID 14520165.
Billiard M et al. Modafinil: A double-blind multicentric study. Sleep vol. Available from: https://academic.oup.com/sleep/article-abstract/17/suppl_8/S107/2749579. Vol. 17; 1994.
Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761-74. doi: 10.1185/030079906X100050, PMID 16684437.
Schwartz J-C. The histamine H3 receptor: from discovery to clinical trials with pitolisant Correspondence; 2011. doi: 10.1111/bph.2010.161.issue-6.
CHMP. Summary of product characteristics. ANNEX I.
Lamb YN. Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs. 2020;34(2):207-18. doi: 10.1007/s40263-020-00703-x, PMID 31997137.
Alachkar A, Łażewska D, Kieć-Kononowicz K, Sadek B. The histamine H3 receptor antagonist E159 reverses memory deficits induced by dizocilpine in passive avoidance and novel object recognition paradigm in rats. Front Pharmacol. 2017;8:709. doi: 10.3389/fphar.2017.00709, PMID 29075190.
Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4, PMID 24107292.
Didikoglu A, Nair N, Robinson AC, Roncaroli F, Pendleton N, Payton A et al. The effect of season of birth on brain epigenome-wide DNA methylation of older adults. J Dev Orig Health Dis. 2022;13(3):367-77. doi: 10.1017/S2040174421000453, PMID 34308828.
Mamelak M, Escriu O, Stokan MJ. 1972;64(166. 19). Oswald I, Jouvet M. Ergebn. Physiol vol. Vol. 22; 1968.
Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev. 2004;8(5):355-66. doi: 10.1016/j.smrv.2004.01.004, PMID 15336236.
Mansukhani MP, Kotagal S. Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: A retrospective study. Sleep Med. 2012;13(6):606-10. doi: 10.1016/j.sleep.2011.10.032, PMID 22445591.
Leu-Semenescu S, Le Corvec T, Groos E, Lavault S, Golmard JL, Arnulf I. Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology. 2015;85(19):1655-62. doi: 10.1212/WNL.0000000000002104, PMID 26453648.
Hishikawa Y, Nan’no H, Tachibana M, Furuya E, Koida H, Kaneko Z. The nature of sleep attack and other symptoms of narcolepsy. Electroencephalogr Clin Neurophysiol. 1968;24(1):1-10. doi: 10.1016/0013-4694(68)90060-6, PMID 4169745.
Mignot E et al. Central (7.1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. Brain Research. Vol. 490; 1989.
Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed). 1985;290(6476):1167-70. doi: 10.1136/bmj.290.6476.1167, PMID 2859077.
Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359-70. doi: 10.1002/ana.25423, PMID 30694576.
Sleep%2F33.11.1457.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16(5):431-43. doi: 10.1016/j.smrv.2011.09.001, PMID 22055895.
Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S. Cataplexy and its mimics: clinical recognition and management. Curr Treat Options Neurol. 2017;19(6):23. doi: 10.1007/s11940-017-0459-0, PMID 28478511.
Manage narcolepsy with psychostimulants based on the individual’s most prominent symptoms, medical history and comorbidities. Drugs Ther Perspect. 2016;32(11):470-5. doi: 10.1007/s40267-016-0342-1.
Wang J, Greenberg H. Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med. 2013;9(7):715-6. doi: 10.5664/jcsm.2848, PMID 23853567.
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200-7. doi: 10.1016/S1474-4422(16)30333-7, PMID 28129985.
Langdon Shindler JD, Parkes N. J. & Bandak, S. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1979;8.
Ruppert E, Zagala H, Chambe J, Comtet H, Kilic-Huck U, Lefebvre F et al. Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. Behav Neurol. 2018;2018:1671072. doi: 10.1155/2018/1671072, PMID 30410634.
Junnarkar G, Allphin C, Profant J, Steininger TL, Chen C, Zomorodi K et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17(2):109-19. doi: 10.1080/17460441.2022.1999226, PMID 34818123.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Naga Prashant Koppuravuri, Sangeetha N, Thasvin U R, T Y Pasha, Rajesh Venkataraman V, V Siva Ganesh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
